WO2005077042A3 - Albumin fusion proteins - Google Patents
Albumin fusion proteins Download PDFInfo
- Publication number
- WO2005077042A3 WO2005077042A3 PCT/US2005/004041 US2005004041W WO2005077042A3 WO 2005077042 A3 WO2005077042 A3 WO 2005077042A3 US 2005004041 W US2005004041 W US 2005004041W WO 2005077042 A3 WO2005077042 A3 WO 2005077042A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fusion proteins
- albumin fusion
- nucleic acids
- vectors
- host cells
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 6
- 108010088751 Albumins Proteins 0.000 title abstract 6
- 102000037865 fusion proteins Human genes 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Abstract
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2554089A CA2554089C (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins |
ES05722848.8T ES2567634T3 (en) | 2004-02-09 | 2005-02-09 | Albumin Fusion Proteins |
KR1020127015659A KR101271635B1 (en) | 2001-12-21 | 2005-02-09 | Albumin fusion proteins |
JP2006553197A JP5010923B2 (en) | 2004-02-09 | 2005-02-09 | Albumin fusion protein |
KR1020067018484A KR101184391B1 (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins |
CN200580012252.5A CN1980687B (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins |
MXPA06009072A MXPA06009072A (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins. |
NZ548612A NZ548612A (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins comprising tandem GLP-1 |
BRPI0507026-0A BRPI0507026A (en) | 2004-02-09 | 2005-02-09 | albumin fusion proteins |
EP05722848.8A EP1729795B1 (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins |
SI200532048T SI1729795T1 (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins |
AU2005211725A AU2005211725B2 (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins |
PL05722848T PL1729795T3 (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins |
DK05722848.8T DK1729795T3 (en) | 2004-02-09 | 2005-02-09 | Albumin fusion proteins |
IL176894A IL176894A (en) | 2004-02-09 | 2006-07-17 | Albumin fusion proteins comprising two or more tandemly oriented glp-1 polypeptides |
US11/495,624 US20080004206A1 (en) | 2001-12-21 | 2006-07-31 | Albumin fusion proteins |
US11/500,508 US7569384B2 (en) | 2004-02-09 | 2006-08-08 | Albumin fusion proteins |
US11/500,314 US20070048282A1 (en) | 2004-02-09 | 2006-08-08 | Albumin fusion proteins |
NO20064059A NO20064059L (en) | 2004-02-09 | 2006-09-08 | Albumin fusion proteins |
HK07101008.1A HK1095087A1 (en) | 2004-02-09 | 2007-01-29 | Albumin fusion proteins |
US11/932,823 US20080194481A1 (en) | 2001-12-21 | 2007-10-31 | Albumin Fusion Proteins |
US12/534,585 US8143026B2 (en) | 2004-02-09 | 2009-08-03 | Albumin fusion proteins |
US12/793,652 US20100291033A1 (en) | 2001-12-21 | 2010-06-03 | Albumin Fusion Proteins |
US12/793,658 US8287859B2 (en) | 2001-12-21 | 2010-06-03 | Methods of reducing toxicity and effects of cocaine by administering a butyrylcholinesterase (BChE)-albumin fusion protein |
AU2010227035A AU2010227035A1 (en) | 2004-02-09 | 2010-10-07 | Albumin fusion proteins |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54227404P | 2004-02-09 | 2004-02-09 | |
US60/542,274 | 2004-02-09 | ||
US54990104P | 2004-03-05 | 2004-03-05 | |
US60/549,901 | 2004-03-05 | ||
US55690604P | 2004-03-29 | 2004-03-29 | |
US60/556,906 | 2004-03-29 | ||
US63660304P | 2004-12-17 | 2004-12-17 | |
US60/636,603 | 2004-12-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/426,882 Continuation-In-Part US20100048472A1 (en) | 2001-12-21 | 2009-04-20 | Albumin Fusion Proteins |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/495,624 Continuation-In-Part US20080004206A1 (en) | 2001-12-21 | 2006-07-31 | Albumin fusion proteins |
US11/500,314 Continuation-In-Part US20070048282A1 (en) | 2004-02-09 | 2006-08-08 | Albumin fusion proteins |
US11/500,508 Continuation-In-Part US7569384B2 (en) | 2001-12-21 | 2006-08-08 | Albumin fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005077042A2 WO2005077042A2 (en) | 2005-08-25 |
WO2005077042A3 true WO2005077042A3 (en) | 2006-11-30 |
Family
ID=34865403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/004041 WO2005077042A2 (en) | 2001-12-21 | 2005-02-09 | Albumin fusion proteins |
Country Status (21)
Country | Link |
---|---|
US (3) | US7569384B2 (en) |
EP (1) | EP1729795B1 (en) |
JP (2) | JP5010923B2 (en) |
KR (1) | KR101184391B1 (en) |
CN (1) | CN102816241B (en) |
AU (2) | AU2005211725B2 (en) |
BR (1) | BRPI0507026A (en) |
CA (1) | CA2554089C (en) |
CY (1) | CY1117401T1 (en) |
DK (1) | DK1729795T3 (en) |
ES (1) | ES2567634T3 (en) |
HK (1) | HK1095087A1 (en) |
HU (1) | HUE027902T2 (en) |
IL (1) | IL176894A (en) |
MA (1) | MA28565B1 (en) |
MX (1) | MXPA06009072A (en) |
NO (1) | NO20064059L (en) |
NZ (1) | NZ548612A (en) |
PL (1) | PL1729795T3 (en) |
SI (1) | SI1729795T1 (en) |
WO (1) | WO2005077042A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
Families Citing this family (177)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | Albumin fusion proteins |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1463752A4 (en) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Albumin fusion proteins |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
US7077176B2 (en) * | 2003-04-28 | 2006-07-18 | Medical Instill Technologies, Inc. | Container with valve assembly for filling and dispensing substances, and apparatus and method for filling |
KR101184391B1 (en) | 2004-02-09 | 2013-03-14 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
RU2401842C2 (en) | 2004-10-08 | 2010-10-20 | Домантис Лимитед | Antagonists and method of using said antagonists |
KR20080071119A (en) * | 2005-08-12 | 2008-08-01 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
US20090099031A1 (en) * | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
JP2009509535A (en) * | 2005-09-27 | 2009-03-12 | アムニクス, インコーポレイテッド | Proteinaceous drugs and their use |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
ES2586236T3 (en) * | 2005-11-04 | 2016-10-13 | Glaxosmithkline Llc | Procedures for administering hypoglycemic agents |
US20080280328A1 (en) * | 2005-11-18 | 2008-11-13 | Novozymes A/S | Glucoamylase Variants |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
ES2543840T3 (en) | 2006-04-11 | 2015-08-24 | Novartis Ag | Spirocyclic HCV / HIV inhibitors and their uses |
JP5566101B2 (en) | 2006-04-24 | 2014-08-06 | メディカル・インスティル・テクノロジーズ・インコーポレイテッド | Needle penetrable and laser resealable freeze-drying apparatus and related methods |
US8334365B2 (en) | 2006-06-07 | 2012-12-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CL2007002634A1 (en) * | 2006-09-13 | 2008-05-16 | Smithkline Beecham Corp | USE OF A COMPOSITION THAT INCLUDES AT LEAST A POLYPEPTIDE THAT HAS A PEPTIDE-1 ACTIVITY LIKE GLUCAGON (GLP-1) AS A LONG-TERM HYPOGLUCEMIAN AGENT. |
BRPI0716744A2 (en) * | 2006-09-14 | 2016-10-04 | Human Genome Sciences Inc | albumin fusion proteins |
WO2008052043A2 (en) * | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
KR20090110295A (en) | 2006-11-22 | 2009-10-21 | 에드넥서스, 어 브리스톨-마이어스 스퀴브 알&디 컴파니 | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
EP2896630B1 (en) | 2007-01-30 | 2020-12-23 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
CA2683791A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains & antagonists |
AU2008275911A1 (en) * | 2007-07-19 | 2009-01-22 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | Self- anchoring MEMS intrafascicular neural electrode |
AU2008287340A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
MX2010001976A (en) * | 2007-09-05 | 2010-03-10 | Sanofi Aventis | Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events. |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
EP2072527A1 (en) | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
WO2009116557A1 (en) * | 2008-03-21 | 2009-09-24 | 富士フイルム株式会社 | Drug-containing composition |
PE20091931A1 (en) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | MULTIVALENT FIBRONECTIN-BASED FRAME DOMAIN PROTEINS |
US20110300127A1 (en) * | 2008-05-27 | 2011-12-08 | Fujifilm Corporation | Drug-containing composition |
EP2373681B1 (en) | 2008-12-10 | 2017-01-18 | Glaxosmithkline LLC | Pharmaceutical compositions of albiglutide |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
PT3178835T (en) | 2009-02-03 | 2019-06-19 | Amunix Pharmaceuticals Inc | Extended recombinant polypeptides and compositions comprising same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
SG2014012918A (en) | 2009-02-11 | 2014-04-28 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
US20110301335A1 (en) | 2009-02-19 | 2011-12-08 | Stephen Duffield | Anti-tnfr1 polypeptides, antibody variable domains & antagonists |
US20120076728A1 (en) * | 2009-04-08 | 2012-03-29 | The Regents Of The University Of California | Human protein scaffold with controlled serum pharmacokinetics |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
KR101286721B1 (en) * | 2009-06-05 | 2013-07-16 | 한국과학기술연구원 | Recombinant albumins fused with poly-cysteine peptide and the methods for preparing the same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
NZ596778A (en) | 2009-06-08 | 2013-11-29 | Amunix Operating Inc | Glucose-regulating polypeptides and methods of making and using same |
WO2011006914A2 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
AU2010277629B2 (en) | 2009-07-29 | 2016-05-19 | Glaxo Group Limited | Anti - TGF - beta receptor type II single domain antibodies |
EP2470559B1 (en) * | 2009-08-24 | 2017-03-22 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
JP2013507978A (en) | 2009-10-27 | 2013-03-07 | グラクソ グループ リミテッド | Stable anti-TNFR1 polypeptides, antibody variable domains and antagonists |
BR112012010110A2 (en) | 2009-10-30 | 2019-09-24 | Boehringer Ingelheim Int | hcv combination therapy dosage regimens comprising bi201335, interferon alfa and ribavirin |
RU2607374C2 (en) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Versions of albumin |
EP2535057A2 (en) | 2010-02-09 | 2012-12-19 | Proyecto de Biomedicina Cima, S.L. | Compositions for the treatment of infectious and tumoural diseases |
CN102762591A (en) | 2010-02-18 | 2012-10-31 | 百时美施贵宝公司 | Fibronectin based scaffold domain proteins that bind il-23 |
US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
CN102939304B (en) | 2010-04-09 | 2017-04-19 | 阿尔布麦狄克斯公司 | albumin derivatives and variants |
US8420098B2 (en) | 2010-04-13 | 2013-04-16 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to PCSK9 |
JP2013525491A (en) | 2010-05-04 | 2013-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
WO2011150133A2 (en) | 2010-05-26 | 2011-12-01 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
EP2585065A1 (en) | 2010-06-24 | 2013-05-01 | Panmed Ltd. | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
WO2012013597A1 (en) * | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Substances and the use thereof for influencing natriuretic peptide receptors |
EP2624826B1 (en) | 2010-10-08 | 2018-07-18 | Novartis AG | Vitamin e formulations of sulfamide ns3 inhibitors |
EP2655411A1 (en) | 2010-12-22 | 2013-10-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind il-23 |
PE20140982A1 (en) | 2011-01-06 | 2014-08-22 | Glaxo Group Ltd | LINKS THAT JOIN THE TRANSFORMANT GROWTH FACTOR-BETA RECEPTOR II |
EP3539991A1 (en) * | 2011-01-07 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
US20120277155A1 (en) | 2011-02-25 | 2012-11-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
JP6101638B2 (en) | 2011-03-03 | 2017-03-22 | ザイムワークス,インコーポレイテッド | Multivalent heteromultimer scaffold design and construction |
WO2012150319A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
EP2750697A4 (en) | 2011-09-02 | 2015-03-25 | Medtronic Inc | Chimeric natriuretic peptide compositions and methods of preparation |
US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
PT2814840T (en) | 2012-02-15 | 2020-01-28 | Bioverativ Therapeutics Inc | Factor viii compositions and methods of making and using same |
JP6383666B2 (en) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | Recombinant factor VIII protein |
PE20142451A1 (en) | 2012-02-27 | 2015-02-04 | Amunix Operating Inc | COMPOSITIONS OF CONJUGATES OF XTEN AND METHODS TO MAKE THEM |
US9603897B2 (en) | 2012-03-12 | 2017-03-28 | Massachusetts Institute Of Technology | Methods for treating tissue damage associated with ischemia with apolipoprotein D |
JP2015509980A (en) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy to treat HCV infection in a population of HCV-HIV co-infected patients |
ES2664328T3 (en) | 2012-03-16 | 2018-04-19 | Albumedix A/S | Albumin variants |
WO2013143581A1 (en) | 2012-03-28 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in specific patient subgenotype sub-population |
US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
AU2013289881B2 (en) | 2012-07-13 | 2018-01-18 | Zymeworks Bc Inc. | Multivalent heteromultimer scaffold design and constructs |
EP2888279A1 (en) | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
EP3564258B1 (en) | 2012-09-13 | 2021-04-28 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
AU2013343503B2 (en) | 2012-11-08 | 2017-12-14 | Albumedix Ltd. | Albumin variants |
US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
USRE48805E1 (en) * | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
ES2843679T3 (en) | 2013-03-06 | 2021-07-20 | Glaxosmithkline Llc | Host cells and methods of use |
EP2968587A2 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
US10344088B2 (en) | 2013-03-15 | 2019-07-09 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
RU2646098C2 (en) | 2013-04-30 | 2018-03-01 | Интас Фармасьютикалс Лтд | New method of cloning, expression and purification for preparation of ranibizumab |
CA2916594C (en) | 2013-07-04 | 2020-03-10 | Novartis Ag | O-mannosyltransferase deficient filamentous fungal cells and methods of use thereof |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
EP3035950A4 (en) * | 2013-08-14 | 2017-05-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases |
CN105377882B (en) * | 2014-03-06 | 2020-05-05 | 葛兰素史密斯克莱有限责任公司 | Host cells and methods of use |
EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
CN108064266A (en) | 2014-07-21 | 2018-05-22 | 格利科斯芬兰公司 | The preparation of the glycoprotein with mammal sample N- glycan in filamentous fungi |
US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
EP3646879B1 (en) | 2014-08-12 | 2024-04-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with integrin-binding-fc-fusion protein and an immune checkpoint inhibitor |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
JP6622814B2 (en) | 2014-11-25 | 2019-12-18 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Novel PD-L1 binding polypeptides for imaging |
BR112017010414A2 (en) | 2014-11-25 | 2018-05-15 | Bristol-Myers Squibb Company | methods and compositions for 18f radiolabeling of biological substances |
CA2971414A1 (en) | 2014-12-19 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
EP3985020A1 (en) | 2015-04-24 | 2022-04-20 | ViiV Healthcare UK (No.5) Limited | Polypeptides targeting hiv fusion |
MX2018001497A (en) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same. |
CN108137674B (en) | 2015-08-20 | 2022-12-06 | 阿尔布梅迪克斯医疗有限公司 | Albumin variants and conjugates |
CN108135968A (en) | 2015-08-28 | 2018-06-08 | 阿穆尼克斯运营公司 | Chimeric polyeptides assembly and its preparation and application |
RU2760582C2 (en) | 2015-09-02 | 2021-11-29 | Иммутеп С.А.С. | Anti-lag-3 antibodies |
EP3348635B1 (en) | 2015-09-08 | 2021-02-17 | JCR Pharmaceuticals CO., LTD. | Novel human serum albumin mutant |
CN108026182B (en) * | 2015-09-18 | 2022-04-26 | 国立大学法人宫崎大学 | Long-acting adrenomedullin derivative |
ES2809125T3 (en) | 2015-09-23 | 2021-03-03 | Bristol Myers Squibb Co | Glypican-3 binding fibronectin-based scaffold molecules |
CN110498851B (en) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | Derivative of antineoplastic protein endostatin and application thereof |
US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
JP7026044B2 (en) * | 2015-12-23 | 2022-02-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Long-acting GLP-1r agonist for the treatment of neurological and neurodegenerative conditions |
WO2017159540A1 (en) * | 2016-03-14 | 2017-09-21 | Jcrファーマ株式会社 | Serum albumin-20 k growth hormone fusion protein |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
EP3827835A1 (en) | 2016-06-16 | 2021-06-02 | Inozyme Pharma, Inc. | Methods of treating myointimal proliferation |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
AU2018207303A1 (en) | 2017-01-10 | 2019-07-25 | xCella Biosciences, Inc. | Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator |
US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
WO2019067502A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) |
CN110090295B (en) * | 2018-01-29 | 2022-12-23 | 武汉康理通科技有限公司 | Application of Ephrin-B1 in preparation of medicine for treating inflammatory bowel disease |
WO2019152827A1 (en) * | 2018-02-02 | 2019-08-08 | AskGene Pharma, Inc. | Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof |
EP3752177A1 (en) | 2018-02-12 | 2020-12-23 | BioNTech RNA Pharmaceuticals GmbH | Treatment using cytokine encoding rna |
BR112020023118A2 (en) | 2018-05-14 | 2021-04-13 | Werewolf Therapeutics, Inc. | ACTIVE ACTIVABLE INTERLEUKIN POLYPEPTIDS 12 AND METHODS OF USE OF THESE |
AU2019271148B2 (en) | 2018-05-14 | 2023-07-06 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
CN112771072A (en) | 2018-07-24 | 2021-05-07 | 生物技术Rna制药有限公司 | IL2 agonists |
JP2022502088A (en) | 2018-09-27 | 2022-01-11 | エクシリオ デベロップメント, インコーポレイテッド | Masked cytokine polypeptide |
KR20210068478A (en) | 2018-09-28 | 2021-06-09 | 메사추세츠 인스티튜트 오브 테크놀로지 | Collagen-localized immunomodulatory molecules and methods thereof |
WO2020154032A1 (en) | 2019-01-23 | 2020-07-30 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
EP3914282A1 (en) | 2019-01-25 | 2021-12-01 | Ospedale San Raffaele S.r.l. | Inhibitor of dux4 and uses thereof |
MX2021009506A (en) | 2019-02-08 | 2021-09-08 | Biontech Cell & Gene Therapies Gmbh | Treatment involving car-engineered t cells and cytokines. |
KR20210143759A (en) | 2019-03-18 | 2021-11-29 | 비온테크 쎌 & 제네 테라피스 게엠베하 | Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells |
WO2020200481A1 (en) | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving interleukin-2 (il2) and interferon (ifn) |
CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
TW202115105A (en) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2 agonists |
JP2022538974A (en) | 2019-06-26 | 2022-09-07 | マサチューセッツ インスチテュート オブ テクノロジー | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
RU2714392C1 (en) * | 2019-07-09 | 2020-02-14 | Екатерина Олеговна Кудасова | Method of modifying the surface of methyl methacrylate of a dental prosthesis with low-temperature gas-discharge plasma of low-pressure oxygen by changing the contact angle of wetting on water and free surface energy |
KR20220044534A (en) | 2019-08-13 | 2022-04-08 | 엘피스 바이오파마슈티컬즈 | Engineered Interleukin-2 Receptor Beta Agonists |
WO2021058091A1 (en) | 2019-09-24 | 2021-04-01 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving therapeutic antibody and interleukin-2 (il2) |
WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
WO2021129945A1 (en) | 2019-12-27 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins) |
JP2023515633A (en) | 2020-02-28 | 2023-04-13 | ブリストル-マイヤーズ スクイブ カンパニー | Radiolabeled fibronectin-based scaffolds and antibodies and their theranostic uses |
WO2021185775A1 (en) | 2020-03-16 | 2021-09-23 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific t cell receptors and t cell epitopes |
WO2021197589A1 (en) | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
WO2021242663A1 (en) | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
JPWO2022030580A1 (en) * | 2020-08-06 | 2022-02-10 | ||
KR102467827B1 (en) * | 2020-08-31 | 2022-11-16 | 연세대학교 산학협력단 | Method for prevent damage that occurs during the microbial aerosolization process |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202245808A (en) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | Therapeutic rna for treating cancer |
CN112753846B (en) * | 2021-01-27 | 2023-08-29 | 吉林农业大学 | Super-water-holding soybean protein isolate gel and preparation method thereof |
WO2022218891A2 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same |
AU2022260466A1 (en) | 2021-04-20 | 2023-11-02 | BioNTech SE | Virus vaccine |
AU2022272733A1 (en) * | 2021-05-14 | 2023-11-30 | Antlia Bioscience, Inc. | Modified b-type natriuretic peptide |
IL308741A (en) | 2021-06-04 | 2024-01-01 | Boehringer Ingelheim Int | Anti-sirp-alpha antibodies |
CN113391067B (en) * | 2021-06-16 | 2023-07-25 | 军事科学院军事医学研究院军事兽医研究所 | Indirect ELISA detection method for anti-Nipah virus G protein antibody |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023066496A1 (en) | 2021-10-21 | 2023-04-27 | BioNTech SE | Coronavirus vaccine |
WO2023067193A2 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Compositions for administration of different doses of rna |
WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
WO2023141638A1 (en) * | 2022-01-21 | 2023-07-27 | The Methodist Hospital System | Methods for vascular regeneration and wound treatment |
WO2023165681A1 (en) | 2022-03-01 | 2023-09-07 | BioNTech SE | Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer |
WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
WO2023220597A1 (en) | 2022-05-10 | 2023-11-16 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta reduced-binding agonist |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024028325A1 (en) | 2022-08-01 | 2024-02-08 | BioNTech SE | Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions |
WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024028445A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
CN115960175A (en) * | 2022-08-08 | 2023-04-14 | 江南大学 | Pichia pastoris for enhancing lactoferrin expression and construction method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506120A (en) * | 1990-10-09 | 1996-04-09 | M & D Research Co., Ltd. | Method of producing peptides or proteins as fusion proteins |
WO2002046227A2 (en) * | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
Family Cites Families (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP2873012B2 (en) | 1987-04-09 | 1999-03-24 | デルタ バイオテクノロジー リミテッド | Yeast vector |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
JPH01215289A (en) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | Production of normal human serum albumin a through gene recombination |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
ZA894792B (en) | 1988-06-24 | 1991-04-24 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
ES2013978A4 (en) | 1988-06-24 | 1990-06-16 | Dow Chemical Co | MACROCYCLIC BIFUNCTIONAL IONIC LINK COMPOUNDS, COMPLEXES OF THEM AND THEIR CONJUGATED ANTIBODIES |
US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
FR2649991B2 (en) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES |
AU4216689A (en) | 1988-08-11 | 1990-03-05 | California Biotechnology, Inc. | Method for stabilizing heterologous protein expression and vectors for use therein |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
DE68925966T2 (en) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
ATE144793T1 (en) | 1989-06-29 | 1996-11-15 | Medarex Inc | BISPECIFIC REAGENTS FOR AIDS THERAPY |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
FR2650598B1 (en) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
WO1991005867A1 (en) | 1989-10-13 | 1991-05-02 | Amgen Inc. | Erythropoietin isoforms |
US5667986A (en) * | 1989-10-18 | 1997-09-16 | Delta Biotechnology Limited | Yeast promoter for expressing heterologous polypeptides |
GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE139258T1 (en) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | GENERATION OF XENOGENE ANTIBODIES |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9013017D0 (en) | 1990-06-11 | 1990-08-01 | Mars Uk Ltd | Compounds |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5225341A (en) | 1990-07-19 | 1993-07-06 | The Regents Of The University Of California | Biologically safe plant transformation system using a ds transposon |
US5202239A (en) | 1990-08-07 | 1993-04-13 | Scios Nova Inc. | Expression of recombinant polypeptides with improved purification |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (en) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
EP0553244B8 (en) | 1990-10-05 | 2005-06-08 | Celldex Therapeutics, Inc. | Targeted immunostimulation with bispecific reagents |
WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
DK1471142T3 (en) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
US5646012A (en) | 1991-04-30 | 1997-07-08 | Rhone-Poulenc Rorer S.A. | Yeast promoter and use thereof |
DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
PT1696031E (en) | 1991-12-02 | 2010-06-25 | Medical Res Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
FR2686620B1 (en) | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | HUMAN SERUM-ALBUMIN, PREPARATION AND USE. |
FR2686900B1 (en) | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
CA2452130A1 (en) | 1992-03-05 | 1993-09-16 | Francis J. Burrows | Methods and compositions for targeting the vasculature of solid tumors |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
SK279710B6 (en) | 1992-06-09 | 1999-02-11 | Hoppe Ag | Lockset system with a latch and process for assembling thereof |
US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
JP4018133B2 (en) | 1992-07-31 | 2007-12-05 | ジェネンテック・インコーポレーテッド | Aqueous preparation of human growth hormone |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
DK82893D0 (en) | 1993-07-08 | 1993-07-08 | Novo Nordisk As | PEPTIDE |
US5512459A (en) | 1993-07-20 | 1996-04-30 | Bionebraska, Inc. | Enzymatic method for modification or recombinant polypeptides |
GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
DK144093D0 (en) * | 1993-12-23 | 1993-12-23 | Novo Nordisk As | |
DK0744958T3 (en) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyclonal antibody libraries |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
US5639642A (en) | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
US5623054A (en) | 1994-06-23 | 1997-04-22 | The General Hospital Corporation | Crucifer AFT proteins and uses thereof |
US5574008A (en) * | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
WO1999014328A2 (en) | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6087129A (en) | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
CA2246431A1 (en) | 1996-01-19 | 1997-07-24 | Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
US6110707A (en) | 1996-01-19 | 2000-08-29 | Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
EP1975177B1 (en) | 1996-03-01 | 2011-04-13 | Novo Nordisk A/S | An appetite-suppressing peptide, its compositions and use |
US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6110703A (en) | 1996-07-05 | 2000-08-29 | Novo Nordisk A/S | Method for the production of polypeptides |
US5959075A (en) | 1996-08-02 | 1999-09-28 | Zymogenetics, Inc. | Testis-specific insulin homolog polypeptides |
US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
AU4199597A (en) | 1996-09-09 | 1998-04-02 | Novo Nordisk A/S | A cdna and peptide with relation to cancer and weight loss |
WO1998012344A1 (en) | 1996-09-18 | 1998-03-26 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP1306092A3 (en) | 1996-11-05 | 2003-05-07 | Eli Lilly & Company | Use of GLP-1 and analogs administered peripherally, in regulation of obesity |
UA65549C2 (en) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
ATE366584T1 (en) | 1996-11-12 | 2007-08-15 | Novo Nordisk As | USE OF GLP-1 PEPTIDES |
CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
WO1998032867A1 (en) | 1997-01-24 | 1998-07-30 | Novo Nordisk A/S | Synthetic leader peptide sequences |
JP2001508783A (en) | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | PEGylation method |
US20030065139A1 (en) * | 1998-03-19 | 2003-04-03 | Craig A. Rosen | Secreted protein hmmbd35 |
US20030175858A1 (en) * | 1997-03-07 | 2003-09-18 | Ruben Steven M. | 186 human secreted proteins |
US6420526B1 (en) * | 1997-03-07 | 2002-07-16 | Human Genome Sciences, Inc. | 186 human secreted proteins |
US20030049618A1 (en) * | 1997-03-07 | 2003-03-13 | Ruben Steven M. | 186 human secreted proteins |
US20060084082A1 (en) * | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
US5981488A (en) * | 1997-03-31 | 1999-11-09 | Eli Lillly And Company | Glucagon-like peptide-1 analogs |
TR199902553T2 (en) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | New methods and uses for the production of antigen receptors against the human body. |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
GB9713412D0 (en) | 1997-06-26 | 1997-08-27 | Delta Biotechnology Ltd | Improved protein expression strains |
MXPA00004256A (en) | 1997-11-03 | 2005-07-01 | Human Genome Sciences Inc | Vegi, an inhibitor of angiogenesis and tumor growth. |
WO1999043706A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
US7205280B2 (en) * | 1998-03-11 | 2007-04-17 | Cognosci, Inc. | Methods of suppressing microglial activation |
AU775422B2 (en) * | 1998-06-15 | 2004-07-29 | Gtc Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion |
MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
US7259136B2 (en) | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
WO2000069911A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US20020048571A1 (en) * | 1999-07-19 | 2002-04-25 | Jeno Gyuris | Chimeric polypeptides of serum albumin and uses related thereto |
EP1200608A2 (en) | 1999-07-19 | 2002-05-02 | GPC Biotech Inc. | Chimeric polypeptides of serum albumin and uses related thereto |
EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | Albumin fusion proteins |
AU6323001A (en) | 2000-05-19 | 2001-12-03 | Bionebraska Inc | Treatment of acute coronary syndrome with glp-1 |
AU775663B2 (en) | 2000-10-20 | 2004-08-12 | Amylin Pharmaceuticals, Inc. | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide |
US7101561B2 (en) * | 2000-12-01 | 2006-09-05 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
WO2002097038A2 (en) | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
US7101843B2 (en) | 2001-08-23 | 2006-09-05 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
US20030228298A1 (en) * | 2001-09-04 | 2003-12-11 | Mark Nesbit | Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis |
AU2002332041A1 (en) * | 2001-10-05 | 2003-04-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ES2556338T3 (en) * | 2001-10-10 | 2016-01-15 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
AU2002353374A1 (en) * | 2001-12-21 | 2003-07-09 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
EP1463752A4 (en) * | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Albumin fusion proteins |
EP2277888A3 (en) * | 2001-12-21 | 2011-04-27 | Human Genome Sciences, Inc. | Fusion proteins of albumin and erythropoietin |
KR101271635B1 (en) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
US20080167238A1 (en) * | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
AU2003226913A1 (en) | 2002-04-04 | 2003-10-20 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
CN1241946C (en) * | 2002-07-01 | 2006-02-15 | 美国福源集团 | Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells |
CA2513213C (en) * | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CN1802386B (en) | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | GLP-1 analog fusion proteins |
KR101184391B1 (en) * | 2004-02-09 | 2013-03-14 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
US20070270339A1 (en) * | 2004-04-23 | 2007-11-22 | Serono, Inc. | Use of GPCR54 Ligands for the Treatment of Infertility |
US20070021336A1 (en) | 2004-12-24 | 2007-01-25 | Christen Anderson | Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis |
DK1888103T3 (en) | 2005-04-11 | 2012-04-23 | Amylin Pharmaceuticals Inc | USE OF GLP-1, EXENDIN AND AGONISTS THEREOF TO DELAY OR PREVENT CARDIAL REMODELING |
KR20080071119A (en) | 2005-08-12 | 2008-08-01 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
EA200870575A1 (en) | 2006-05-26 | 2009-08-28 | Амилин Фармасьютикалз, Инк. | COMPOSITIONS AND METHODS OF TREATMENT OF CONSTITUAL HEART FAILURE |
US8334365B2 (en) | 2006-06-07 | 2012-12-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2008019143A2 (en) | 2006-08-04 | 2008-02-14 | Amylin Pharmaceuticals, Inc | Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition |
JP5005450B2 (en) * | 2007-07-13 | 2012-08-22 | 本田技研工業株式会社 | Internal structure of fuel supply pipe mouth |
-
2005
- 2005-02-09 KR KR1020067018484A patent/KR101184391B1/en active Protection Beyond IP Right Term
- 2005-02-09 HU HUE05722848A patent/HUE027902T2/en unknown
- 2005-02-09 SI SI200532048T patent/SI1729795T1/en unknown
- 2005-02-09 BR BRPI0507026-0A patent/BRPI0507026A/en not_active Application Discontinuation
- 2005-02-09 DK DK05722848.8T patent/DK1729795T3/en active
- 2005-02-09 EP EP05722848.8A patent/EP1729795B1/en active Active
- 2005-02-09 CN CN201210139189.3A patent/CN102816241B/en not_active Expired - Fee Related
- 2005-02-09 CA CA2554089A patent/CA2554089C/en not_active Expired - Fee Related
- 2005-02-09 AU AU2005211725A patent/AU2005211725B2/en not_active Ceased
- 2005-02-09 MX MXPA06009072A patent/MXPA06009072A/en active IP Right Grant
- 2005-02-09 NZ NZ548612A patent/NZ548612A/en not_active IP Right Cessation
- 2005-02-09 WO PCT/US2005/004041 patent/WO2005077042A2/en active Application Filing
- 2005-02-09 JP JP2006553197A patent/JP5010923B2/en not_active Expired - Fee Related
- 2005-02-09 PL PL05722848T patent/PL1729795T3/en unknown
- 2005-02-09 ES ES05722848.8T patent/ES2567634T3/en active Active
-
2006
- 2006-07-17 IL IL176894A patent/IL176894A/en active IP Right Grant
- 2006-08-08 US US11/500,508 patent/US7569384B2/en not_active Expired - Fee Related
- 2006-08-08 US US11/500,314 patent/US20070048282A1/en not_active Abandoned
- 2006-09-08 MA MA29305A patent/MA28565B1/en unknown
- 2006-09-08 NO NO20064059A patent/NO20064059L/en not_active Application Discontinuation
-
2007
- 2007-01-29 HK HK07101008.1A patent/HK1095087A1/en not_active IP Right Cessation
-
2009
- 2009-08-03 US US12/534,585 patent/US8143026B2/en active Active
-
2010
- 2010-10-07 AU AU2010227035A patent/AU2010227035A1/en not_active Abandoned
-
2012
- 2012-02-28 JP JP2012041914A patent/JP5568582B2/en not_active Expired - Fee Related
-
2016
- 2016-04-18 CY CY20161100318T patent/CY1117401T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506120A (en) * | 1990-10-09 | 1996-04-09 | M & D Research Co., Ltd. | Method of producing peptides or proteins as fusion proteins |
WO2002046227A2 (en) * | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
Non-Patent Citations (1)
Title |
---|
BAGGIO L.L. ET AL: "A Recombinant Human Glucagon-Like Peptide (GLP)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis", DIABETES, vol. 53, September 2004 (2004-09-01), pages 2492 - 2500, XP003004469 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9221896B2 (en) | 2001-12-21 | 2015-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9296809B2 (en) | 2001-12-21 | 2016-03-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005077042A3 (en) | Albumin fusion proteins | |
WO2007021494A3 (en) | Albumin fusion proteins | |
WO2008033413A3 (en) | Albumin fusion proteins | |
WO2007146038A3 (en) | Albumin fusion proteins | |
WO2005003296A3 (en) | Albumin fusion proteins | |
WO2003060071A3 (en) | Albumin fusion proteins | |
WO2001079443A3 (en) | Albumin fusion proteins | |
WO2003059934A3 (en) | Albumin fusion proteins | |
WO2003030821A3 (en) | Albumin fusion proteins | |
WO2006119987A3 (en) | Recombinant n-glycosylated proteins from procaryotic cells | |
WO2007104529A3 (en) | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
WO2002002624A3 (en) | B7-like molecules and uses thereof | |
WO2002024891A3 (en) | B7-like molecules and uses thereof | |
WO2001092308A3 (en) | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof | |
WO2001070977A3 (en) | Fibroblast growth factor receptor-like molecules and uses thereof | |
WO2001068854A3 (en) | Fibroblast growth factor-like molecules and uses thereof | |
WO2006017355A3 (en) | Improved aprotinin variants | |
WO2001042474A3 (en) | Interferon-like molecules and uses thereof | |
WO2003087338A3 (en) | Her-2 receptor tyrosine kinase molecules and uses thereof | |
WO2006122971A3 (en) | Treatment of disease using an improved regulated expression system | |
WO2002102316A3 (en) | Histone deacetylase and methods of use thereof | |
WO2002097046A3 (en) | B7 related protein-2 molecules and uses thereof | |
WO2005054286A3 (en) | Interleukin-11 fusion proteins | |
WO2004058949A3 (en) | Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof | |
WO2005023979A3 (en) | Isolated s. mansoni nucleic acid molecules and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/05871 Country of ref document: ZA Ref document number: 176894 Country of ref document: IL Ref document number: 200605871 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005211725 Country of ref document: AU Ref document number: 2554089 Country of ref document: CA Ref document number: 548612 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006501460 Country of ref document: PH Ref document number: 4362/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11495624 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11500508 Country of ref document: US Ref document number: 11500314 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/009072 Country of ref document: MX Ref document number: 2006553197 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2005211725 Country of ref document: AU Date of ref document: 20050209 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005211725 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005722848 Country of ref document: EP Ref document number: DZP2006000447 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 06089815 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067018484 Country of ref document: KR Ref document number: 1200601476 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006132384 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580012252.5 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005722848 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11500508 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067018484 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 11500314 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0507026 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 11495624 Country of ref document: US |